Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.

[1]  R. Avery.  Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52). , 2016, Ophthalmology.

[2]  R. Guymer,et al.  Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. , 2015, Ophthalmology.

[3]  M. Gillies,et al.  REASONS FOR DISCONTINUATION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[4]  R. Guymer,et al.  ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION: A Treat-and-Extend Protocol Over 2 Years , 2014, Retina.

[5]  U Chakravarthy,et al.  The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. , 2014, Ophthalmology.

[6]  J. Keeffe,et al.  EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES: The Fight Retinal Blindness! Project , 2014, Retina.

[7]  B. Kirchhof,et al.  Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. , 2013, American journal of ophthalmology.

[8]  R. Guymer,et al.  Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. , 2013, Investigative ophthalmology & visual science.

[9]  P. Ng,et al.  A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[10]  Allen C Ho,et al.  Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.

[11]  A. Ho,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[12]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[13]  C. Regillo,et al.  Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. , 2012, American journal of ophthalmology.

[14]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[15]  R. Tadayoni,et al.  INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED: A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration , 2011, Retina.

[16]  C. Regillo,et al.  A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.

[17]  R. Spaide.  Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.

[18]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[19]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[20]  Terje R Pedersen,et al.  Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. , 2015, Ophthalmology.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  Allen C Ho,et al.  Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2014, Ophthalmology.

[23]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[24]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .

[25]  T. Hastie,et al.  Statistical Models in S , 1991 .